Skip to main content
. 2019 Oct 30;3(4):e11266. doi: 10.2196/11266

Table 2.

Baseline and posttest scores for fear of movement and secondary outcomes (N=16).

Measure Baseline Posttest Effect size (95% CI) MCIDa, n (%)
Kinesiophobia, mean (SD)

FDAQb 59.20 (24.83) 56.45 (21.02) −0.15 (−0.55, 0.25) 6 (38)

POQ-VAc Fear 12.44 (5.01) 11.91 (3.01) −0.10 (−0.69, 0.48) N/Ad
Outliers excludede

FDAQ 60.28 (25.31) 54.75 (20.58) −0.35 (−0.71, 0.01) f

POQ-VA Fear 12.31 (2.65) 12.07 (4.95) 0.06 (−0.47, 0.59)
Pain outcomes (POQ-VA), mean (SD)

Interfere daily living 16.44 (12.36) 17.33 (12.03) 0.10 (−0.27, 0.47) N/A

Interfere mobility 26.31 (9.58) 22.25 (10.82) −0.56 (−0.96, −0.16) N/A

Negative affect 28.56 (10.96) 29.09 (11.87) 0.07 (−0.26, 0.40) N/A
Numeric Rating Scale, mean (SD)

Pain intensity 6.88 (1.26) 6.38 (1.59) −0.48 (−0.87, −0.10) 1 (7)

Outlier excluded 6.73 (1.16) 6.40 (1.64) −0.40 (−0.69, −0.12)
PCSg 28.83 (10.39) 24.54 (15.45) −0.41 (−0.79, −0.02) 5 (36)
PSFSh 3.60 (1.59) 5.98 (2.37) 1.14 (0.50, 1.78) 10 (67)

aMCID: minimum clinically important difference.

bFDAQ: Fear of Daily Activities Questionnaire.

cPOQ-VA: Pain Outcomes Questionnaire-VA.

dNot applicable.

eN=15.

fMCID not recalculated.

gPCS: Pain Catastrophizing Scale.

hPSFS: Patient-Specific Functioning Scale.